Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?

Breast (Edinburgh, Scotland) - 1 Aug 2015

Abreu M H, Gomes M, Menezes F, Afonso N, Abreu P H, Medeiros R, Pereira D, Lopes C

Abstract excerpt

BACKGROUND: Tamoxifen remains the standard hormonotherapy for Male breast cancer patients (MBC). Previous studies, in women, tried to evaluate the impact of CYP2D6 polymorphisms in tamoxifen efficacy with conflicting results. Herein we analyze the relation between CYP2D6*4 polymorphism and survival in MBC patients. PATIENTS AND METHODS: Fifty-three patients, proposed to tamoxifen in adjuvant setting, were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms, Male

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Cytochrome P-450 CYP2D6

Share to Mastectomy

Share to Neoplasm Recurrence, Local

Share to Pharmacogenetics

Share to Tamoxifen

Source

Identifiers

PMID: 25963137
DOI: 10.1016/j.breast.2015.04.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?PMID 25963137Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.Semantic proximity Read ↗

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Semantic proximity Read ↗

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.Semantic proximity Read ↗

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.Semantic proximity Read ↗

Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.Semantic proximity Read ↗

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Semantic proximity Read ↗

Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in São Luís, Brazil, and its association with prognostic factors and disease-free survival.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.